Tomohiko Ohta, MD

Articles by Tomohiko Ohta, MD

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

ByMamoru Fukuda, MD,Susumu Yamaguchi, MD,Tomohiko Ohta, MD,Yoshiaki Nakayama, MD,Haruki Ogata, MD,Kaname Shimizu, MD,Toru Nishikawa, MD,Yukihiro Adachi, MD,Eisuke Fukuma, MD

July 1st 1999

We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), uracil and tegafur (UFT), and tamoxifen (Nolvadex) (CAUT), designed as

Latest Updated Articles

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen
July 1st 1999

Trending on CancerNetwork

How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?

FDA Accepts Protocol Amendment to Phase 3 NANORAY-312 Trial in HNSCC

Cevostamab May Fill Gap in Multiple Myeloma Armamentarium

Radiological Features/Serum PSA May Predict Prostate Cancer Survival

131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)